title: Post-treatment bone marrow residual disease > 5% by flow cytometry is highly predictive of short progression-free and overall survival in patients with Waldenström's macroglobulinemia.
abstract: To assess the value of bone marrow (BM) assessment by flow cytometry FCM after therapy in the clinical outcome of WM patients, we analyzed 42 WM patients who were evaluated before and after therapy. Patients were studied with a panel that always included the CD19, CD22, CD25, and κ/λ light chain immunoglobulin monoclonal antibodies. The mean of abnormal B-cells in the pre-therapeutic BM was 17.8% ± 12.1%, which decreased was after therapy to 5.4% ± 0.7% (P = .049). A linear correlation was seen between the better quality of response and the reduction in the tumor B-lymphocyte counts at the BM, since the ratio of abnormal B cells between pre and posttherapy BM was 1172.17, 221.64, 3.37, 1.03, and 0.56 for responses complete, partial, minor, stable disease and progression, respectively (P < .001). Intensive and rituximab-containing therapies correlated with deeper tumor cell reductions. Finally, the B-cell decrease correlated with the better overall and progression-free survival.
authors.affiliation: Hospital Universitario de Salamanca, University of Salamanca, Spain.
authors.forename: R
authors.initials: R
authors.lastname: García-Sanz
authors.forename: Em
authors.initials: E
authors.lastname: Ocio
authors.forename: A
authors.initials: A
authors.lastname: Caballero
authors.forename: R J P
authors.initials: RJ
authors.lastname: Magalhães
authors.forename: J
authors.initials: J
authors.lastname: Alonso
authors.forename: L
authors.initials: L
authors.lastname: López-Anglada
authors.forename: T
authors.initials: T
authors.lastname: Villaescusa
authors.forename: N
authors.initials: N
authors.lastname: Puig
authors.forename: J M
authors.initials: JM
authors.lastname: Hernández
authors.forename: J
authors.initials: J
authors.lastname: Fernández-Calvo
authors.forename: A
authors.initials: A
authors.lastname: Aguilar
authors.forename: A
authors.initials: A
authors.lastname: Martín
authors.forename: R
authors.initials: R
authors.lastname: López
authors.forename: B
authors.initials: B
authors.lastname: Paiva
authors.forename: A
authors.initials: A
authors.lastname: Orfao
authors.forename: B
authors.initials: B
authors.lastname: Vidriales
authors.forename: J F
authors.initials: JF
authors.lastname: San-Miguel
authors.forename: D
authors.initials: D
authors.lastname: Del Carpio
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018941:Antigens, CD19 / Q000378:metabolism; D001853:Bone Marrow / Q000473:pathology*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D016130:Immunophenotyping; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual; D011379:Prognosis; D008258:Waldenstrom Macroglobulinemia / Q000175:diagnosis* / Q000401:mortality*
chemical_list: D018941:Antigens, CD19